• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 4, 2017

View Archived Issues

Astellas buys GPCR drug developer Ogeda for €500M up front; up to €300M more

Astellas Pharma Inc. is buying Belgium's Ogeda SA for €500 million (US$532.7 million) up front and up to €300 million in milestone payments tied to the clinical and regulatory advancement of fezolinetant, a midstage nonhormonal treatment for menopause-related vasomotor symptoms (MR-VMS). If successful, it could potentially broaden the options for women seeking an alternative to estrogens and progestogens, which though commonly used to treat MR-VMS, have been associated with heightened risks of breast cancer, stroke and thromboembolism. Read More

In the clinic

Caladrius Biosciences Inc., of Basking Ridge, N.J., said it added four sites to its phase II trial of CLBS03 in type 1 diabetes, the Sanford Project: T-Rex Study, helping to meet the enrollment goal of 111 patients. Read More

Other news to note

Veloxis Pharmaceuticals A/S, of Copenhagen, said its U.S. subsidiary inked an exclusive license, supply and distribution agreement with Taiba Healthcare, of Muscat, Oman, to register, commercialize and distribute Envarsus XR (tacrolimus) in certain countries throughout the Middle East and North Africa, or MENA, region. Read More

VC investments hit status quo but no complaints here

Last year wasn't the best for venture capital investments in U.S. private companies, with the total for the year headed in the wrong direction, failing to match 2015 levels. (See BioWorld Today, Jan. 4, 2017.) Read More

Bristol-Myers Squibb gets much-needed I-O boost on Opdivo OS data

Bristol-Myers Squibb Co. (BMS) fell back in the immuno-oncology (I-O) pack last year after reporting that its blockbuster, Opdivo (nivolumab), failed to achieve statistically significant progression-free survival (PFS) in the phase III CHECKMATE-026 trial testing the PD-1 immune checkpoint inhibitor as a monotherapy vs. platinum-based chemo in patients with first-line non-small-cell lung cancer (NSCLC) whose tumors express PD-L1 at greater than 5 percent. Read More

Anatomy and avatars matter in molecularly targeted trials

WASHINGTON – Data from the Heracles and SUMMIT trials presented at the 2017 annual meeting of the American Association for Cancer Research confirmed that HER2-targeting drugs, which were originally developed for breast cancer, can be useful both for treating other tumor types and for patients whose HER2 gene is mutated but who do not overexpress HER2 protein. Read More

The research 3 Rs: Rigor, reproducibility and robustness

WASHINGTON – As scientists gathered at the 2017 meeting of the American Association for Cancer Research (AACR) to learn about the latest advances in cancer research, one of the questions was how much of that research would hold up to attempts to reproduce it. Read More

CGI, Mendel alliance will use patient data to drive better cancer outcomes

Diagnostics player Cancer Genetics Inc. (CGI) has paired up with artificial intelligence (AI) company Mendel Health to incorporate deep learning into clinical trial matching. Read More

Regulatory front

The U.S. SEC released a final rule making technical amendments to the Jumpstart Our Business Startups (JOBS) Act and adjusting caps on crowdfunding and emerging growth companies (EGC) to reflect inflation. Read More

Financings

Tocagen Inc., of San Diego, has filed to offer 7.25 million shares priced at $10 to $12 per share in its IPO. The company plans to list on Nasdaq under the ticker symbol TOCA. Read More

AACR 2017

Essa Pharma Inc., of Vancouver, British Columbia, said EPI-506 remained well-tolerated through six cohorts of patients with metastatic castration-resistant prostate cancer at escalating doses in its ongoing phase I trial. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe